3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Papillomavirus Infections
1
Oropharyngeal Neoplasms
1
Melanoma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma
1
Carcinoma, Non-Small-Cell Lung
1
Advanced/Metastatic Solid Tumors
1
Interventions
Gemcitabine
25
Cisplatin
19
pembrolizumab
11
avelumab
10
Nivolumab
7
Mitomycin
6
Carboplatin
6
apaziquone
5
Paclitaxel
5
Vinblastine
4
Methotrexate
4
Doxorubicin
4
Docetaxel
4
BCG Vaccine
4
vofatamab
3
durvalumab
3
atezolizumab
3
Sunitinib
3
Standard of Care
3
Sorafenib
3
Radiotherapy, Intensity-Modulated
3
Radiotherapy
3
Radiation
3
Magnetic Resonance Spectroscopy
3
Lapatinib
3
Cystectomy
3
B701 protein, Human herpesvirus 6
3
valrubicin
2
rucaparib
2
enfortumab vedotin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Urinary Bladder Neoplasms
×
utomilumab
×
Clear all
NCT02554812
2024-07-30
JAVELIN Medley
Pfizer
Phase 1/2
Terminated
409 enrolled
108 charts